Quarterly report pursuant to Section 13 or 15(d)

Balance Sheet Components

v3.19.3
Balance Sheet Components
9 Months Ended
Sep. 30, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Balance Sheet Components

NOTE 6 — BALANCE SHEET COMPONENTS

Accrued liabilities consisted of the following (in thousands):

 

 

 

September 30,

 

 

December 31,

 

 

 

2019

 

 

2018

 

Accrued liabilities:

 

 

 

 

 

 

 

 

General and administrative

 

$

619

 

 

$

297

 

Clinical trial related costs

 

 

1,696

 

 

 

598

 

Non-clinical research and manufacturing operations

 

 

4,796

 

 

 

2,644

 

Payroll related

 

 

1,950

 

 

 

1,787

 

Other accrued expenses

 

 

44

 

 

 

31

 

Total Accrued liabilities

 

$

9,105

 

 

$

5,357

 

 

At September 30, 2019 and December 31, 2018, the Company had $13.2 million and $28.9 million, respectively, of Deferred revenue related to research and development agreements.